Adlimumab, Humira

Human

CSB104B pdf (datasheet)

1.0 mg

$1,480.00 BUY

1.0 mg/ml

Adalimumab is a TNF inhibiting, anti-inflammatory biologic medication. It is the first fully human monoclonal therapeutic antibody. TNF alpha bound to its receptor leads to the inflammatory response associated with autoimmune diseases. Adalimumab binds specifically to TNF alpha, neutralizes the biological function by blocking its interaction with p55 and p75 cell surface TNF receptors. By this mechanism, adalimumab reduces the inflammatory response associated with autoimmune diseases. Adalimumab has been shown to reduce the symptoms of rheumatoid arthritis, Crohn's disease, plaque psoriasis, among others. Adalimumab was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. A new biosimilar to adalimumab, named adalimumab-adaz, was approved by the FDA on October 31, 2018. This biosimilar is known as Hyrimoz, and is a trademark of Novartis AG 9.

TNF

P01375

> 95% as determined by SDS-PAGE

Binds to soluble TNF alpha, but not to TNF beta.

Human

IgG1 Kappa light chain

PBS, Ph 7.5

ELISA, FS

Store at -20°C to -80°C for up to 1 year.